Previous close | 0.0100 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.0100 |
Strike | 27.00 |
Expiry date | 2024-05-24 |
Day's range | 0.0100 - 0.0300 |
Contract range | N/A |
Volume | |
Open interest | 2.06k |
The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.